Atrium Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNA research report →
Companywww.atriumtherapeutics.com
Atrium Therapeutics, Inc. , a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
- CEO
- Kathleen Gallagher
- IPO
- 2026
- Employees
- 511
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $218.89M
- P/E
- -3.38
- P/S
- 10.68
- P/B
- 0.94
- EV/EBITDA
- 0.71
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.26%
- Op Margin
- -318.70%
- Net Margin
- -315.71%
- ROE
- -29.67%
- ROIC
- -23.91%
Growth & Income
- Revenue
- $18.62M · 0.00%
- Net Income
- $-76,684,000 · 0.00%
- EPS
- $-4.48 · 0.00%
- Op Income
- $-76,814,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $16.77
- 52W Low
- $11.95
- 50D MA
- $13.43
- 200D MA
- $13.66
- Beta
- 0.00
- Avg Volume
- 742.54K
Get TickerSpark's AI analysis on RNA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RNA Coverage
We haven't published any research on RNA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RNA Report →